The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase 3 trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥2 line recurrent or metastatic cervical cancer.
 
Krishnansu Sujata Tewari
Consulting or Advisory Role - Roche/Genentech
Speakers' Bureau - AstraZeneca; Merck; Roche/Genentech
Travel, Accommodations, Expenses - Roche/Genentech
 
Ignace Vergote
Consulting or Advisory Role - Amgen (Inst); Array Biopharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); GE Healthcare (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Intuitive Surgical (Inst); Janssen-Cilag (Inst); Lilly (Inst); MedImmune (Inst); Menarini (Inst); Merck Sharp & Dohme (Inst); Morphotek (Inst); Nektar (Inst); Novo Nordisk (Inst); Oasmia Pharmaceutical AB (Inst); PharmaMar (Inst); Phillips Gilmore Oncology (Inst); Roche (Inst); Sanofi (Inst); Schering-Plough (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Fresenius Biotech (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Janssen-Cilag (Inst); Karyopharm Therapeutics (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Merrimack (Inst); Morphotek (Inst); Nektar (Inst); Nerviano Medical Sciences (Inst); Novartis (Inst); Pfizer (Inst); Quintiles (Inst); Roche (Inst); Sandoz (Inst); Sanofi (Inst); Schering-Plough (Inst); Tesaro (Inst); Vifor Pharma (Inst); Wyeth (Inst)
Travel, Accommodations, Expenses - AstraZeneca; GCI Health; Oasmia Pharmaceutical AB; PharmaMar; Roche
 
Ana Oaknin
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; PharmaMar; Roche; Tesaro
Travel, Accommodations, Expenses - AstraZeneca; PharmaMar; Roche
 
Edwin Alvarez
Consulting or Advisory Role - TRACON Pharma
Research Funding - AstraZeneca
Travel, Accommodations, Expenses - Intuitive Surgical
 
Dana Meredith Chase
Speakers' Bureau - Roche
Research Funding - Genentech (Inst)
 
Stephanie Gaillard
Honoraria - Merck; Merck
Consulting or Advisory Role - Genentech/Roche; Merck; Pfizer; Tesaro
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Gradalis (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); PharmaMar (Inst); TetraLogic Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Sermonix Pharmaceuticals
 
Stephanie Lheureux
Consulting or Advisory Role - AstraZeneca; AstraZeneca
 
Danny Rischin
Research Funding - Amgen; Bristol-Myers Squibb; Genentech/Roche; Merck; Regeneron
 
Alessandro Santin
No Relationships to Disclose
 
Minjie Feng
Employment - Bayer; Regeneron
Stock and Other Ownership Interests - Bayer; Regeneron
 
Melissa Mathias
No Relationships to Disclose
 
Matthew G. Fury
Employment - Regeneron; Regeneron (I)
Stock and Other Ownership Interests - Regeneron; Regeneron (I)
Consulting or Advisory Role - Egenix
Research Funding - AstraZeneca/MedImmune; Novartis; Regeneron
Patents, Royalties, Other Intellectual Property - Regeneron (I)
 
Israel Lowy
Employment - Regeneron
Leadership - Regeneron
Stock and Other Ownership Interests - Regeneron
Travel, Accommodations, Expenses - Regeneron
 
Bradley J. Monk
Leadership - US Oncology
Honoraria - Abbvie; Advaxis; Amgen; AstraZeneca; Bayer; Biodesix; Cerulean Pharma; Clovis Oncology; GlaxoSmithKline; Gradalis; Immunogen; Incyte; Insys Therapeutics; Janssen; Mateon Therapeutics; Merck; Myriad Pharmaceuticals; Nucana; Oxigene; Oxigene; Perthera; Pfizer; Precision Oncology; Roche/Genentech; Tesaro; Verastem; Vermillion
Consulting or Advisory Role - Abbvie; Advaxis; Amgen; AstraZeneca; Bayer; Biodesix; Cerulean Pharma; Clovis Oncology; GlaxoSmithKline; Gradalis; Immunogen; Incyte; Insys Therapeutics; Mateon Therapeutics; Merck; Myriad Pharmaceuticals; Nucana; Oxigene; Perthera; Pfizer; Precision Oncology; Roche/Genentech; Tesaro; Verastem; Vermillion
Speakers' Bureau - AstraZeneca; Clovis Oncology; Janssen; Roche/Genentech; Tesaro
Research Funding - Advaxis (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Genentech (Inst); Immunogen (Inst); Janssen (Inst); Lilly (Inst); Morphotek (Inst); Novartis (Inst); Nucana (Inst); Pfizer (Inst); Regeneron (Inst); Tesaro (Inst)